Skip to main content
. Author manuscript; available in PMC: 2009 Dec 1.
Published in final edited form as: Neurobiol Aging. 2007 Jun 6;29(12):1795–1804. doi: 10.1016/j.neurobiolaging.2007.04.023

Figure 2. The reduction of NMDAR-EPSC by physostigmine is mainly mediated by nicotinic acetylcholine receptors.

Figure 2

A. Plot of normalized NMDAR-EPSC amplitudes as a function of time and physostigmine (40 µM) application in neurons treated with either atropine (50 µM) or benzoquinonium (BZQ, 50 µM). B. Current traces taken from the records used to construct A (at time points denoted by #). Scale bars: 10pA/100ms. C. Bar plot summary showing the percentage reduction of NMDAR-EPSC by physostigmine in the presence of atropine, BZQ, atropine + BZQ, or MLA (10 µM) + DHβE (0.1 µM). *: p < 0.001, t-test.